Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss the novel aspects of topical therapies used for the treatment of AD. We also discuss the lapses observed when comparing topical therapies. After the innovations regarding systemic therapies in AD were highlighted in a first review (part 1), this second component (part 2) will perceive the advances in topical therapies for AD. RECENT FINDINGS: Recent history has realized a prompt evolution in the options for topical therapy in AD. Novel, molecularly targeted topical therapies appear to address the drawbacks of traditional topical medicines. SUMMARY: The transformation towards targeted AD therapies is associated with increased efficacy and safety profiles, as well as patient compliance. We also evaluate available real-world and long-term data. Future studies should focus on optimizing topical therapies by increasing the duration of available long-term data.